Database for
Therapeutic Antibodies
Therapeutic Antibodies
| Entry ID | 2281 |
| INN | Motavizumab |
| Status | Terminated |
| Drug code(s) | MEDI524 |
| Brand name | Numax |
| mAb sequence source | mAb humanized |
| General Molecular Category | Naked monospecific |
| Format, general category | Full length Ab |
| Format details | None |
| Isotype (Fc) | IgG1 |
| Light chain isotype | kappa |
| Linker | None |
| Ave. DAR | None |
| Conjugated/fused moiety | None |
| Discovery method/technology | None |
| Target(s) | RSV (F glycoprotein) |
| Indications of clinical studies | Prevention of RSV infection in high risk infants |
| Primary therapeutic area | Infectious diseases |
| Most advanced stage of development (global) | Terminated at regulatory review |
| Status | Inactive |
| Start of clinical phase (IND filing or first Phase 1) | January 15, 2000 |
| Start of Phase 2 | |
| Start of Phase 3 | October 15, 2004 |
| Date BLA/NDA submitted to FDA | |
| Year of first approval (global) | None |
| Date of first US approval | |
| INN, US product name | None |
| US or EU approved indications | None |
| Company | AstraZeneca |
| Licensee/Partner | None |
| Comments about company or candidate | None |
| Full address of company | Cambridge, United Kingdom Europe United Kingdom https://www.astrazeneca.com/our-company/contact-us.html |
Motavizumab, an affinity-optimized version of palivizumab, was developed to improve protection against RSV. These antibodies bind RSV F protein, which plays a role in virus attachment and mediates fusion. Described in J Virol. 2010 Aug;84(16):8132-40. doi: 10.1128/JVI.02699-09.
| Anticipated events | None |
| Factor(s) contributing to discontinuation | None |